Australia · Delayed Price · Currency is AUD Syntara Earnings Call Transcripts
Fiscal Year 2026
-
Formal FDA alignment on the phase II-B trial for imsulostat de-risks the clinical path and enhances partnering prospects. A recent AUD 8 million capital raise extends the cash runway to Q3 2027, funding multiple clinical milestones and supporting ongoing licensing discussions.
-
Syntara highlighted its diversified late-stage pipeline, with multiple clinical readouts expected in the next 12 months. Lead asset amsulostat showed strong efficacy and safety in myelofibrosis, while skin scarring and Parkinson’s programs are advancing with significant commercial interest.
-
Entering 2026 with a strong cash position and five clinical trials, the pipeline is set for multiple data readouts, with amsulostat leading in myelofibrosis and MDS. Flexible partnering options and non-dilutive funding support broad optionality and capital efficiency.
Fiscal Year 2025
-
Scarring remains a major unmet need with no approved therapies that remodel tissue at the biological level. SNT-9465, a next-generation pan-LOX inhibitor, showed promising safety and mechanistic results in early studies and is now in a rigorously designed phase 1b trial for hypertrophic sternotomy scars.
-
The meeting highlighted strong clinical progress, robust financial health, and a diversified pipeline with key data readouts expected in the next year. Voting was completed on all resolutions except one withdrawn item, and the company remains well positioned for future growth.
-
The conference showcased Syntara's progress with its diverse clinical pipeline, highlighting strong efficacy and safety data for its lead asset in myelofibrosis, upcoming regulatory milestones, and multiple catalysts expected in 2025. Immutep was also introduced, with its lead immunotherapy in a global phase 3 lung cancer trial.
-
Final phase 2A data for amsulastat in myelofibrosis showed 73% of patients achieved major symptom reduction, with strong spleen volume responses and no drug-related withdrawals. Six of seven completers opted to continue treatment, and new expert advisors have joined to guide the next development phase.
-
FDA guidance requires a separate phase II-B trial for amsulostat, extending timelines but providing a clear path to approval and supporting future partnering. Funding options remain robust, with a cash runway to 2027 and multiple ongoing studies expected to generate value.
-
Interim phase II data for SNT-5505 in advanced myelofibrosis show strong symptom and spleen volume improvements, with a favorable safety profile and no drug-related hematological toxicity. FDA fast-track status and upcoming regulatory discussions support advancement to phase III.
-
Strong cash reserves support an 18-month runway as multiple clinical programs advance, with key SNT-5505 myelofibrosis data to be presented at EHA in June and regulatory feedback expected in Q3. Skin scarring and Parkinson’s studies also progress, with data due next year.
-
The conference highlighted a robust pipeline targeting fibrosis and blood cancers, with lead asset SNT 5505 showing strong efficacy and safety in myelofibrosis. Multiple studies are set to deliver key data in 2024, and new skin scarring and Parkinson’s programs are advancing.
-
The meeting covered four key resolutions related to share placements, director participation, advisor fees, and capacity refresh, with all votes conducted online. Updates were provided on clinical data timelines and pharma interest, and voting results will be released to the exchange.
-
Strong institutional backing, a diversified late-stage pipeline, and significant cost reductions position the company for key data readouts in December and throughout 2025, with a solid cash runway and multiple non-dilutive grants supporting ongoing studies.
Fiscal Year 2024
-
Interim results for SNT5505 in myelofibrosis show strong symptom and spleen responses, with about 60% of patients achieving significant symptom improvement and a favorable safety profile. The drug may offer a competitive option for patients with limited alternatives.
-
The meeting highlighted a year of transformation, cost reduction, and strategic focus on advancing the lead asset SNT-5505, with new clinical studies and external funding secured. All resolutions were presented and voting conducted, with results to be released post-meeting.